Athira Pharma, Inc. (ATHA)

NASDAQ: ATHA · IEX Real-Time Price · USD
2.85
+0.06 (2.15%)
Jun 29, 2022 12:44 PM EDT - Market open
2.15%
Market Cap 107.26M
Revenue (ttm) n/a
Net Income (ttm) -66.97M
Shares Out 37.64M
EPS (ttm) -1.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 611,716
Open 2.77
Previous Close 2.79
Day's Range 2.70 - 2.85
52-Week Range 2.53 - 16.65
Beta n/a
Analysts Buy
Price Target 11.22 (+293.7%)
Earnings Date Aug 15, 2022

About ATHA

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-101... [Read more...]

Industry Biotechnology
IPO Date Sep 18, 2020
Employees 34
Stock Exchange NASDAQ
Ticker Symbol ATHA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for ATHA stock is "Buy." The 12-month stock price forecast is 11.22, which is an increase of 293.68% from the latest price.

Price Target
$11.22
(293.68% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Athira Pharma stock loses two-thirds of its value after study of Alzheimer's treatment misses primary endpoint

Shares of Athira Pharma Inc. apha plummeted 66.9% toward a record low in active afternoon trading Wednesday, enough to make them the biggest decliners trading on major market indexes, after the biopharm...

Athira Pharma shares drop nearly 70% on release of clinical trial data for Alzheimer's disease

Athira Pharma's stock plummeted nearly 70% Wednesday after a clinical trial testing its candidate drug for Alzheimer's disease failed to meet its primary endpoint.

Why Athira Pharma Stock Imploded Today

Its mid-stage clinical trial failed to help patients with Alzheimer's.

Athira Pharma (ATHA) Stock Plunges 65% on Disappointing Drug Trial Results

Athira Pharma (ATHA) stock is plummeting on Wednesday following the outcome of a Phase 2 clinical trial of fosgonimeton. The post Athira Pharma (ATHA) Stock Plunges 65% on Disappointing Drug Trial Resul...

Athira Pharma Shares Fall To 52-Week Low - Read Why

Athira Pharma Inc (NASDAQ: ATHA) shares are falling to 52-week lows after announcing disappointing topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton (ATH-1017) in mild-to-moderat...

Why Athira Pharma Stock Is Plunging

Athira Pharma Inc (NASDAQ: ATHA) shares are falling Wednesday after the company announced topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate Alzh...

Athira says its Alzheimer's treatment did not meet endpoint in mid-stage trial; stock falls 68%

Shares of Athira Pharma Inc. ATHA, -1.74% tumbled 68.0% in premarket trading on Wednesday after the company said an exploratory Phase 2 study assessing its experimental treatment for patients with mild-...

Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderat...

Primary endpoint of change in biomarker ERP P300 latency was not statistically significant for the full study population as combination of fosgonimeton and standard-of-care (AChEIs) given together showe...

Athira Pharma Announces Formation of Scientific Advisory Board Comprised of Renowned Leaders in Neurology Research

BOTHELL, Wash., June 07, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and...

ATHIRA PHARMA INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Inves...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigatio...

ATHIRA ALERT: Bragar Eagel & Squire, P.C. Is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders an...

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Athira Pharma, Inc. (NASDAQ: ATHA) on beh...

Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual Meeting

BOTHELL, Wash., May 19, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and ...

Athira Issues Statement in Response to Richard A. Kayne's Suspension of His Proxy Contest

Athira Board Unanimously Recommends Shareholders Vote “FOR” its Highly Qualified Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card

Ric Kayne Suspends Campaign to Elect Himself and George Bickerstaff to Athira Pharma Board of Directors

NEW YORK--(BUSINESS WIRE)--Richard A. (Ric) Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc. (NASDAQ: ATHA) (...

Ric Kayne Issues Letter to Athira Shareholders Highlighting Need for Immediate Change to Athira Board

NEW YORK--(BUSINESS WIRE)--Richard A. (Ric) Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc. (NASDAQ: ATHA) (...

Athira Urges Shareholders to Support its Director Nominees at May 19 Annual Meeting

Urges Shareholders to Vote TODAY “FOR” Athira's Highly Qualified, Independent Director Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE Proxy Card

ATHIRA PHARMA INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Inves...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigatio...

Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Athira Shareholders Vote “FOR” All of Athira's Hi...

Joins Institutional Shareholder Services in Recommending a Vote on Athira's WHITE Proxy Card

Leading Proxy Advisory Firm ISS Recommends Athira Shareholders “Withhold” Support From Incumbent Directors Joseph Ede...

NEW YORK--(BUSINESS WIRE)--Richard A. (Ric) Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc. (NASDAQ: ATHA) (...

Leading Independent Proxy Advisory Firm ISS Recommends that Athira Shareholders Vote on Athira's WHITE Proxy Card

Athira Urges Shareholders to Vote “FOR” Athira's Highly Qualified, Independent Director Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE Proxy Card Today

Ric Kayne Identifies Highly Qualified CEO Candidate for Athira

NEW YORK--(BUSINESS WIRE)--Richard A. (Ric) Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc. (NASDAQ: ATHA) (...

Ric Kayne Issues Letter to Athira Shareholders Highlighting Why Immediate Board Change Is Required

NEW YORK--(BUSINESS WIRE)--Richard A. (Ric) Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc. (NASDAQ: ATHA) (...

Ric Kayne Publishes Investor Presentation Highlighting Urgent Need for Changes to Athira's Board of Directors

NEW YORK--(BUSINESS WIRE)--Richard A. (Ric) Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc. (NASDAQ: ATHA) (...

Athira Mails Letter to Shareholders Highlighting the Strength of its Board and Record of Deliberate Board Refreshment

Urges shareholders to vote “FOR” Athira's highly qualified, independent director nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card

ATHIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders an...

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Athira Pharma, Inc. (NASDAQ: ATHA) on beh...